A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors

Trial Profile

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Tislelizumab (Primary)
  • Indications Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 10 Feb 2018 Preliminary results (data cut off: 18 jun 2017; n=15) in a subset of patients with urothelial carcinoma presented at the 2018 Genitourinary Cancers Symposium.
    • 09 Feb 2018 According to a BeiGene media release, preliminary clinical data presented at the 2018 Genitourinary Cancers Symposium.
    • 09 Feb 2018 Results published in the BeiGene Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top